Open access · CC-BY
via OpenAlex
Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial
Rebecca H. Maier, Bilal Bawamia, Karim Bennaceur, Sarah Dunn, Leanne Marsay, Roland Amoah, Adetayo Kasim, Andrew J. Filby, David Austin, Helen C. Hancock, Ioakim Spyridopoulos
JMIR Research Protocols · 2020 · ▲ 20 citations
Telomere attrition
Cellular senescence
Chronic inflammation
Telomerase activation
Cell culture / in vitro
Human
Randomized controlled trial
Preclinical / animal
In vitro
Abstract
BACKGROUND: Inflammation plays a key role in the pathophysiology of coronary heart disease (CHD) and its acute manifestation, acute coronary syndrome (ACS). Aging is associated with a decline of the immune system, a process known as immunosenescence. This is characterized by an increase in highly proinflammatory T cells that are involved in CHD progression, plaque destabilization, and myocardial ischemia-reperfusion injury. Telomere(definition) dysfunction has been implicated in immunosenescence of T lymphocytes. Telomerase is the enzyme responsible for maintaining telomeres during cell divisions. It has a protective effect on cells under oxidative stress and helps regulate flow-mediated dilation in microvasculature. OBJECTIVE: The TACTIC (Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome) trial will investigate whether a telomerase activator, TA-65MD, can reduce the proportion of senescent T cells in patients with ACS with confirmed CHD. It will also assess the effect of TA-65MD on decreasing telomere shortening, reducing oxidative stress, and improving endothelial function. METHODS: The study was designed as a single-center, randomized, double-blind, parallel-group, placebo-controlled phase II trial. Recruitment started in January 2019. A total of 90 patients, aged 65 years or older, with treated ACS who have had CHD confirmed by angiography will be enrolled. They will be randomized to one of two groups: TA-65MD oral therapy (8 mg twice daily) or placebo taken for 12 months. The primary outcome is the effect on immunosenescence determined by a decrease in the proportion of CD8+ TEMRA (T effector memory cells re-expressing CD45RA [CD45 expressing exon A]) cells at 12 months. Secondary outcomes include leukocyte telomere length, endothelial function, cardiac function as measured by echocardiography and NT-proBNP (N-terminal fragment of the prohormone brain-type natriuretic peptide), systemic inflammation, oxidative stress, and telomerase activity. RESULTS: The study received National Health Service (NHS) ethics approval on August 9, 2018; Medicines and Healthcare products Regulatory Agency approval on October 19, 2018; and NHS Health Research Authority approval on October 22, 2018. The trial began recruiting participants in January 2019 and completed recruitment in March 2020; the trial is due to report results in 2021. CONCLUSIONS: This pilot trial in older patients with CHD will explore outcomes not previously investigated outside in vitro or preclinical models. The robust design ensures that bias has been minimized. Should the results indicate reduced frequency of immunosenescent CD8+ T cells as well as improvements in telomere length and endothelial function, we will plan a larger, multicenter trial in patients to determine if TA-65MD is beneficial in the treatment of CHD in elderly patients. TRIAL REGISTRATION: ISRCTN Registry ISRCTN16613292; http://www.isrctn.com/ISRCTN16613292 and European Union Drug Regulating Authorities Clinical Trials Database (EudraCT), European Union Clinical Trials Register 2017-002876-26; https://tinyurl.com/y4m2so8g. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/19456.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.2196/19456
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
Maier, R.H., Bawamia, B., Bennaceur, K., Dunn, S., Marsay, L., Amoah, R., Kasim, A., Filby, A.J., Austin, D., Hancock, H.C., & Spyridopoulos, I. (2020). Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial. <em>JMIR Research Protocols</em>. https://doi.org/10.2196/19456
Vancouver
Maier RH, Bawamia B, Bennaceur K, Dunn S, Marsay L, Amoah R, et al. Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial. JMIR Research Protocols. 2020. doi:10.2196/19456.
BibTeX
@article{rebecca2020Telome,
title = {Telomerase Activation to Reverse Immunosenescence in Elderly Patients With Acute Coronary Syndrome: Protocol for a Randomized Pilot Trial},
author = {Rebecca H. Maier and Bilal Bawamia and Karim Bennaceur and Sarah Dunn and Leanne Marsay and Roland Amoah and Adetayo Kasim and Andrew J. Filby and David Austin and Helen C. Hancock and Ioakim Spyridopoulos},
journal = {JMIR Research Protocols},
year = {2020},
doi = {10.2196/19456},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cellular and Molecular Life Sciences 2017
Open access · CC-BY
Telomerase and drug resistance in cancer
Tang-Du Hospital 2026
Open access · US-GOV
Multicenter, Single-arm, Phase II Exploratory Study of Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
Journal of the American College of Cardiology 2007
Open access · OA
Telomere Length of Circulating Leukocytes Is Decreased in Patients With Chronic Heart Failure
The Lancet Healthy Longevity 2021
Open access · CC-BY
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
Trials 2024
Open access · CC-BY
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) in elderly patients: Study protocol for a multicenter, randomized, adaptive allocation clinical trial
Vestre Viken Hospital Trust 2024
Open access · US-GOV